AIM: Small-scale clinical studies have reported on drug interactions between caspofungin (CPFG) and calcineurin inhibitors in healthy subjects; however, little is known about these interactions in allogeneic haematopoietic cell transplantation (allo-HCT) patients. METHODS: We retrospectively assessed the drug interactions and safety profiles in allo-HCT recipients treated concomitantly with CPFG and calcineurin inhibitors. RESULTS: Ninety-one consecutive cases were evaluated. There were no statistically significant differences in the plasma concentration/dose (C/D) ratios of tacrolimus (TAC) in 34 patients before and after co-administration with CPFG (median: 575.6-672.4, P = 0.200). In contrast, the median C/D ratio of cyclosporin A (CsA) in 16 patients was significantly elevated after co-administration with CPFG (median: 62.8-74.9, P = 0.016). There were no serious adverse effects on liver or renal function associated with the therapy. CONCLUSIONS: Our data show that CPFG did not affect the pharmacokinetics of TAC and that it could mildly increase CsA blood concentrations in allo-HCT patients.
AIM: Small-scale clinical studies have reported on drug interactions between caspofungin (CPFG) and calcineurin inhibitors in healthy subjects; however, little is known about these interactions in allogeneic haematopoietic cell transplantation (allo-HCT) patients. METHODS: We retrospectively assessed the drug interactions and safety profiles in allo-HCT recipients treated concomitantly with CPFG and calcineurin inhibitors. RESULTS: Ninety-one consecutive cases were evaluated. There were no statistically significant differences in the plasma concentration/dose (C/D) ratios of tacrolimus (TAC) in 34 patients before and after co-administration with CPFG (median: 575.6-672.4, P = 0.200). In contrast, the median C/D ratio of cyclosporin A (CsA) in 16 patients was significantly elevated after co-administration with CPFG (median: 62.8-74.9, P = 0.016). There were no serious adverse effects on liver or renal function associated with the therapy. CONCLUSIONS: Our data show that CPFG did not affect the pharmacokinetics of TAC and that it could mildly increase CsA blood concentrations in allo-HCT patients.
Authors: Punam Sandhu; Wooin Lee; Xin Xu; Brenda F Leake; Masayo Yamazaki; Julie A Stone; Jiunn H Lin; Paul G Pearson; Richard B Kim Journal: Drug Metab Dispos Date: 2005-02-16 Impact factor: 3.922
Authors: A Glasmacher; O A Cornely; K Orlopp; S Reuter; S Blaschke; M Eichel; G Silling; B Simons; G Egerer; M Siemann; M Florek; R Schnitzler; P Ebeling; J Ritter; H Reinel; P Schütt; H Fischer; C Hahn; G Just-Nuebling Journal: J Antimicrob Chemother Date: 2005-11-24 Impact factor: 5.790
Authors: Stephen Ph Alexander; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: R Trenschel; M Ditschkowski; A H Elmaagacli; M Koldehoff; H Ottinger; N Steckel; M Hlinka; R Peceny; P-M Rath; H Dermoumi; D W Beelen Journal: Bone Marrow Transplant Date: 2005-03 Impact factor: 5.483
Authors: C Sanz-Rodriguez; M Lopez-Duarte; M Jurado; J Lopez; R Arranz; J-M Cisneros; M L Martino; P J Garcia-Sanchez; P Morales; T Olivé; M Rovira; C Solano Journal: Bone Marrow Transplant Date: 2004-07 Impact factor: 5.483